EX-FILING FEES 5 ea191455ex-fee_abvcbio.htm FILING FEES EXHIBIT

Exhibit 107

 

CALCULATION OF FILING FEE TABLES

 

FORM S-1

 

ABVC BioPharma, Inc.

 

Table 1: Newly Registered and Carry Forward Securities

 

   Security
Type
  Security
Class Title
  Fee
Calculation
or Carry
Forward
Rule(1)
  Amount
Registered
   Proposed
Maximum
Offering
Price Per
Unit
   Maximum
Aggregate
Offering Price
   Fee Rate   Amount of
Registration
Fee (4)
   Carry
Forward
Form
Type
   Carry
Forward
File
Number
   Carry
Forward
Initial
effective
date
   Filing Fee
Previously
Paid In
Connection
with Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
Fees to be paid  Equity  Common Stock, $0.001 par value, issuable upon conversion of the 2nd Lind Note  457(i)   342,857   $        3.5(2)   $17,270,671    0.00014760    $$2,549.15                      
Fees to be paid  Equity  Common Stock, $0.001 par value, issuable upon exercise of the 2nd  Lind Warrant  457(c)   1,000,000   $2(3)  $2,000,000    0.00014760    $$295.20           
  Equity  Common Stock, $0.001 par value, issuable upon exercise of the PA Warrant  457(c)   30,000   $2 (3)  $60,000    0.00014760    $$8.86                                  
Fees previously paid                                                      
   Total Offering Amounts        $19,330,671        $2,853.21                     
   Total Fees Previously Paid                  $-                     
   Total Fee Offsets                  -                     
   Net Fee Due                  $2,853.21                     

 

(1)Pursuant to Rule 416 under the Securities Act, the shares registered hereby also include an indeterminate number of additional shares as may from time to time become issuable by reason of stock splits, distributions, recapitalizations or other similar transactions.

 

(2)Represents the number of shares of Common Stock underlying the principal amount of the 2nd Lind Note, based on the initial exercise price of $3.50, subject to adjustment. The conversion price of the 2nd Lind Note shall be the lesser of (i) $3.50 (the “Fixed Price”), (ii) 90% of the three lowest VWAPs (as defined in the 2nd Lind Note) during the 20 trading days prior to conversion, provided however that so long as no Event of Default (as defined in the 2nd Lind Note) shall have occurred, the conversion price shall be at the Fixed Price for the first 180 days following the closing date.

 

(3)Represents the number of shares of Common Stock underlying the 2nd Lind Warrant and 2nd PA Warrant, based on the initial exercise price of $2 per share, subject to adjustment.

 

(4)Calculated by multiplying the proposed maximum aggregate offering price of securities to be registered by the Fee Rate.

 

 

 

 

Table 2: Combined Prospectuses (1)

 

Security Type  Security Class Title  Amount of
Securities
Previously
Registered
   Maximum
Aggregate
Offering Price
of Securities
Previously
Registered
   Form Type  File Number  Initial
Effective
Date
Equity  Common Stock, $0.001par value, issuable upon conversion of the Lind Note   3,527,778(2)  $3,704,167.00   S-1  333-271416  June 8, 2023
Equity  Common Stock, $0.001 par value, issuable upon exercise of the Lind Warrant   5,291,677   $3,492,506.82(3)  S-1  333-271416  June 8, 2023
Equity  Common Stock, $0.001 par value, issuable upon exercise of the PA Warrant   211,667   $139,700.22(3)  S-1  333-271416  June 8, 2023

 

(1)Pursuant to Rule 457(b) and Rule 429, no separate registration fee is payable with respect to the primary issuance or resale of such securities, as such securities were previously registered on the Prior Registration Statement.

 

(2)Represents the number of shares of Common Stock underlying the principal amount of the Lind Note, based on the initial exercise price of $1.05, subject to adjustment.

 

(3)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) of the Securities Act. The proposed maximum offering price per share is estimated to be $0.66, based on the average of the high ($0.69) and low ($0.63) sales prices of the Common Stock as reported by the Nasdaq Capital Market on April 20, 2023.